FDA Moves On NDA For First US OTC Birth Control, Scheduling Joint Ad Comm Meeting
Executive Summary
The US FDA has scheduled a joint advisory committee meeting for November to review Perrigo subsidiary HRA Pharma’s new drug application for Rx-to-OTC switch of Opill (0.075-mg norgestrel), which would represent the first birth control pill available in the US without a prescription.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
Dobbs Decision Could Have Knock-On Effects For Wider Reproductive Healthcare Landscape
The US Supreme Court’s overturning of Roe v. Wade, which enshrined the right to an abortion in the Constitution for almost 50 years, could have consequences that extend beyond access to termination of pregnancy.
Age-Restriction Labeling, Behind-The-Counter Sales Likely In HRA's US OTC Contraceptive NDA
“I think the issue is whether it is going to have age restricted labeling, which would be a political issue rather than a medical issue,” says